Low p14 super(ARF) expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis

The TP53 tumor suppressor pathway is abrogated by TP53 mutations in the majority of human cancers. Increased levels of wild-type TP53 in aggressive neuroblastomas appear paradox but are tolerated by tumor cells due to co-activation of the TP53 ubiquitin ligase, MDM2. The role of the MDM2 antagonist,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human molecular genetics 2013-05, Vol.22 (9), p.1735-1745
Hauptverfasser: Dreidax, Daniel, Gogolin, Sina, Schroeder, Christina, Muth, Daniel, Brueckner, Lena Marie, Hess, Elisa Maria, Zapatka, Marc, Theisen, Jessica, Fischer, Matthias, Ehemann, Volker, Schwab, Manfred, Savelyeva, Larissa, Westermann, Frank
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The TP53 tumor suppressor pathway is abrogated by TP53 mutations in the majority of human cancers. Increased levels of wild-type TP53 in aggressive neuroblastomas appear paradox but are tolerated by tumor cells due to co-activation of the TP53 ubiquitin ligase, MDM2. The role of the MDM2 antagonist, p14 super(ARF), in controlling the TP53-MDM2 balance in neuroblastoma is unresolved. In the present study, we show that conditional p14 super(ARF) expression substantially suppresses viability, clonogenicity and anchorage-independent growth in p14 super(ARF)-deficient or MYCN-amplified neuroblastoma cell lines. Furthermore, ectopic 14 super(ARF) expression induced accumulation of cells in the G1 phase and apoptosis, which was paralleled by accumulation of TP53 and its targets. Comparative genomic hybridization analysis of 193 primary neuroblastomas detected one homozygous deletion of CDKN2A (encoding both p14 super(ARF) and p16 super(INK4A)) and heterozygous loss of CDKN2A in 22% of tumors. Co-expression analysis of p14 super(ARF) and its transactivator, E2F1, in a set of 68 primary tumors revealed only a weak correlation, suggesting that further regulatory mechanisms govern p14 super(ARF) expression in neuroblastomas. Intriguingly, analyses utilizing chromatin immunoprecipitation revealed different histone mark-defined epigenetic activity states of p14 super(ARF) in neuroblastoma cell lines that correlated with endogenous p14 super(ARF) expression but not with episomal p14 super(ARF) promoter reporter activity, indicating that the native chromatin context serves to epigenetically repress p14 super(ARF) in neuroblastoma cells. Collectively, the data pinpoint p14 super(ARF) as a critical factor for efficient TP53 response in neuroblastoma cells and assign p14 super(ARF) as a neuroblastoma suppressor candidate that is impaired by genomic loss and epigenetic repression.
ISSN:0964-6906
1460-2083
DOI:10.1093/hmg/ddt020